December 16, 2011
The test confidently detects HLA-B*5701 to help decrease risk of abacavir hypersensitivity reaction.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its HLA-B*5701 screening test1 is now commercially available in Europe. HLA-B*5701 screening provides physicians with a means to avoid prescribing drugs to patients at high risk of allergic reactions to a drug called abacavir for the treatment of HIV and AIDS.
As recommended by the US Department of Health and Human Services (DHHS), the European AIDS Clinical Society, and the International AIDS Society-USA Panel (IAS),2,3,4 all patients should be screened for the HLA-B*5701 allele before starting or restarting treatment with abacavir or abacavir-containing medications. Avoidance of abacavir therapy in HLA-B*5701 positive patients will significantly decrease the risk of developing clinically-suspected abacavir hypersensitivity reactions (HSR).
Abacavir is a prescription medication that is used as a treatment for HIV and AIDS. Serious and sometimes fatal HSR caused by abacavir therapy are significantly more common in patients with a particular human leukocyte antigen (HLA) allele, HLA-B*5701.5,6 The US Department of Health and Human Services (DHHS) and the International AIDS Society-USA Panel (IAS) have recommended that all patients are screened prior to initiating abacavir containing regimens.
About COBAS® AmpliPrep / COBAS® TaqMan® System
The Roche HLA-B*5701 Screening Test runs on the fully automated COBAS® AmpliPrep/COBAS® TaqMan® System.1 The platform combines the COBAS® AmpliPrep Instrument for automated sample preparation and the COBAS® TaqMan® Analyzer or the smaller COBAS® TaqMan® 48 Analyzer for automated real-time PCR amplification and detection. The COBAS AmpliPrep/COBAS TaqMan System has parallel processing with other key molecular diagnostics assays targeting medically relevant diseases (Hepatitis B virus, Hepatitis C virus, and Human Immunodeficiency Virus). Roche’s AmpErase enzyme is also included in each test and is designed to prevent cross reactivity and minimize testing errors in labs.
According to UNAIDS, there were 33.3 million people living with HIV around the world in 2009. In that same year, 2.6 million people became newly infected with HIV— almost 20 percent fewer than in the late 1990s.7 Highly active antiretroviral treatment (HAART) and viral load tests, a test to determine the amount of circulating HIV, have contributed to a steady increase in life expectancy for HIV infected people by 13 years.8
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.